Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Standalone Viewers  
Protein Workshop | Ligand Explorer

Global Symmetry: Cyclic - C2  (3D View)
Global Stoichiometry: Homo 2-mer - A2 

Biological assembly 1 assigned by authors.

Macromolecule Content

• Total Structure Weight: 63046.26 
• Atom Count: 4271 
• Residue Count: 548 
• Unique protein chains: 1

1KNU

LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA IN COMPLEX WITH A SYNTHETIC AGONIST

• DOI: 10.2210/pdb1KNU/pdb

• Classification: DNA BINDING PROTEIN
• Organism(s): Homo sapiens
• Expression System: Escherichia coli BL21(DE3)


• Deposited: 2001-12-19 Released: 2002-12-19 
• Deposition Author(s): Svensson, L.A., Mortensen, S.B., Fleckner, J., Woeldike, H.F.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.5 Å
• R-Value Free: 0.264 
• R-Value Work: 0.224 

Literature

Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity

Sauerberg, P., Pettersson, I., Jeppesen, L., Bury, P.S., Mogensen, J.P., Wassermann, K., Brand, C.L., Sturis, J., Woldike, H.F., Fleckner, J., Andersen, A.-S.T., Mortensen, S.B., Svensson, L.A., Rasmussen, H.B., Lehmann, S.V., Polivka, Z., Sindelar, K., Panajotova, V., Ynddal, L., Wulff, E.M.

(2002) J.MED.CHEM. 45: 789-804

• PubMed: 11831892 


• PubMed Abstract: 
  

Synthesis and structure-activity relationships of tricyclic alpha-ethoxy-phenylpropionic acid derivatives guided by in vitro PPARalpha and PPARgamma transactivation data and computer modeling led to the identification of the novel carbazole analogue, 3q, with dual PPARalpha (EC(50) = 0.36 microM) and PPARgamma (EC(50) = 0.17 microM) activity in vitro. Ten days treatment of db/db mice with 3q improved the insulin sensitivity, as measured by OGTT, better than that seen with both pioglitazone and rosiglitazone treatment, suggesting in vivo PPARgamma activity. Likewise, 3q lowered plasma triglycerides and cholesterol in high cholesterol fed rats after 4 days treatment, indicating in vivo PPARalpha activity. Investigations of the pharmacokinetics of selected compounds suggested that extended drug exposure improved the in vivo activity of in vitro active compounds.

---

Organizational Affiliation: 

Novo Nordisk A/S, Novo Nordisk Park E9 2.02, 2760 Måløv, Denmark. [e-mail]

Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA	A, B	274	Homo sapiens	Mutation(s): 0  Gene Names: PPARG (NR1C3)
Find proteins for P37231 (Homo sapiens) Go to Gene View: PPARG Go to UniProtKB:  P37231

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram & Interactions
YPA	A	(S)-3-(4-(2-CARBAZOL-9-YL-ETHOXY)-PHENYL)-2-ETHOXY-PROPIONIC ACID C25 H25 N O4 WUZIMDSVRIBNNI-DEOSSOPVSA-N

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
YPA	Kd: 170 nM (100) BINDINGDB
YPA	EC50: 170 nM (100) BINDINGDB

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.5 Å
• R-Value Free: 0.264 
• R-Value Work: 0.224 
• Space Group: C 1 2 1

Unit Cell:

Length (Å)	Angle (°)
a = 92.270	α = 90.00
b = 63.440	β = 101.84
c = 119.240	γ = 90.00

Software Package:

Software Name	Purpose
CNX	phasing
XDS	data scaling
CNX	refinement
XDS	data reduction

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2001-12-19 
• Released Date: 2002-12-19 
• Deposition Author(s): Svensson, L.A., Mortensen, S.B., Fleckner, J., Woeldike, H.F.

Revision History 

• Version 1.0: 2002-12-19
  Type: Initial release
• Version 1.1: 2008-04-27
  Type: Version format compliance
• Version 1.2: 2011-07-13
  Type: Version format compliance
• Version 1.3: 2017-10-11
  Type: Data collection, Refinement description